Russia has extended a government authorization allowing Promomed to produce a generic version of Novo Nordisk’s Ozempic without the patent holder’s consent through 2027.
The Russian government has approved a decree permitting domestic pharmaceutical company Promomed to continue using a portfolio of patents owned by Denmark’s Novo Nordisk covering semaglutide, the active ingredient in Ozempic.
The authorization will remain in effect until December 31, 2027. Authorities said the extension was justified by an “urgent need related to protecting public life and health.”
Promomed first received the exemption in December 2023. The company currently markets four semaglutide-based drugs: Kvinsenta, Semaltara, Velgia and Velgia Eco.
According to data from CRPT, the operator of Russia’s national labeling system “Chestny Znak,” sales of domestic Ozempic equivalents reached 6.1 million packages in 2025, generating 35.2 billion rubles (about $492.8 million) in revenue. Sales nearly tripled compared with 2024, with growth continuing into early 2026. In the first half of January alone, 333,000 packages were sold, up 17% year-on-year.
Sources: Kommersant, Vademecum
